SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
- PMID: 38640902
- PMCID: PMC11084874
- DOI: 10.1016/j.chembiol.2024.03.008
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Abstract
Over four years have passed since the beginning of the COVID-19 pandemic. The scientific response has been rapid and effective, with many therapeutic monoclonal antibodies and small molecules developed for clinical use. However, given the ability for viruses to become resistant to antivirals, it is perhaps no surprise that the field has identified resistance to nearly all of these compounds. Here, we provide a comprehensive review of the resistance profile for each of these therapeutics. We hope that this resource provides an atlas for mutations to be aware of for each agent, particularly as a springboard for considerations for the next generation of antivirals. Finally, we discuss the outlook and thoughts for moving forward in how we continue to manage this, and the next, pandemic.
Keywords: COVID-19; SARS-CoV-2; antibody; antiviral; drug resistance; small-molecule inhibitor.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests S.I. and D.D.H. have sponsored research agreements with Enanta Pharmaceuticals, Shionogi & Co., Ltd., and Regeneron Pharmaceuticals. S.I. and D.D.H. are inventors on patent applications related to SARS-CoV-2 monoclonal antibodies as well as to SARS-CoV-2 3CL protease inhibitors. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics, Brii Biosciences, Apexigen, and Veru Inc., and board director for Vicarious Surgical.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
